Barclays PLC Grows Position in agilon health, inc. (NYSE:AGL)

Barclays PLC grew its holdings in agilon health, inc. (NYSE:AGL) by 21.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,228,952 shares of the company’s stock after buying an additional 214,830 shares during the period. Barclays PLC’s holdings in agilon health were worth $4,830,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of AGL. XTX Topco Ltd increased its holdings in shares of agilon health by 271.1% in the third quarter. XTX Topco Ltd now owns 119,747 shares of the company’s stock valued at $471,000 after purchasing an additional 87,481 shares during the last quarter. State Street Corp grew its holdings in agilon health by 3.0% in the 3rd quarter. State Street Corp now owns 7,449,706 shares of the company’s stock valued at $29,277,000 after buying an additional 215,733 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of agilon health in the 3rd quarter worth $261,000. Point72 DIFC Ltd purchased a new position in shares of agilon health during the 3rd quarter worth $99,000. Finally, Holocene Advisors LP acquired a new position in shares of agilon health during the 3rd quarter valued at about $714,000.

Insiders Place Their Bets

In related news, Director Diana Mckenzie acquired 12,500 shares of the business’s stock in a transaction on Monday, November 25th. The shares were bought at an average price of $2.28 per share, with a total value of $28,500.00. Following the completion of the acquisition, the director now owns 51,319 shares in the company, valued at $117,007.32. This trade represents a 32.20 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Karen Mcloughlin bought 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $2.20 per share, with a total value of $55,000.00. Following the acquisition, the director now owns 73,166 shares in the company, valued at approximately $160,965.20. This represents a 51.90 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 90,000 shares of company stock valued at $198,100 in the last ninety days. Insiders own 3.20% of the company’s stock.

agilon health Stock Up 4.8 %

Shares of NYSE:AGL opened at $1.97 on Friday. agilon health, inc. has a fifty-two week low of $1.50 and a fifty-two week high of $13.28. The firm’s 50 day moving average price is $2.32 and its 200 day moving average price is $4.25. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.06. The stock has a market cap of $811.68 million, a price-to-earnings ratio of -2.10 and a beta of 0.51.

agilon health (NYSE:AGL) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). The firm had revenue of $1.45 billion during the quarter, compared to analyst estimates of $1.47 billion. agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. During the same quarter in the previous year, the business posted ($0.06) earnings per share. As a group, equities research analysts predict that agilon health, inc. will post -0.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AGL has been the topic of several analyst reports. TD Cowen reduced their price target on shares of agilon health from $6.00 to $2.00 and set a “hold” rating on the stock in a research report on Monday, November 11th. William Blair downgraded agilon health from an “outperform” rating to a “market perform” rating in a research report on Friday, November 8th. Barclays lowered their price target on agilon health from $5.00 to $2.00 and set an “underweight” rating for the company in a report on Monday, November 11th. Evercore ISI decreased their target price on shares of agilon health from $7.00 to $4.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 8th. Finally, JMP Securities downgraded shares of agilon health from an “outperform” rating to a “market perform” rating in a research note on Monday, November 11th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.28.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.